---
title: 'Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy:
  Primary analysis of the ELM-1 study'
date: '2025-01-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39786390/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20250109170931&v=2.18.0.post9+e462414
source: Blood
description: Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma
  (DLBCL) progressing after chimeric antigen receptor T-cell therapy (CAR T) have
  dismal outcomes. The prespecified post-CAR T expansion cohort of the ELM-1 study
  investigated the efficacy and safety of odronextamab, a CD20×CD3 bispecific antibody,
  in patients with disease progression after CAR T. Sixty patients received IV odronextamab
  weekly for 4 cycles followed by maintenance until progression. The primary endpoint
  ...
disable_comments: true
---
Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) progressing after chimeric antigen receptor T-cell therapy (CAR T) have dismal outcomes. The prespecified post-CAR T expansion cohort of the ELM-1 study investigated the efficacy and safety of odronextamab, a CD20×CD3 bispecific antibody, in patients with disease progression after CAR T. Sixty patients received IV odronextamab weekly for 4 cycles followed by maintenance until progression. The primary endpoint ...